OCUL Stock Overview
A biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Ocular Therapeutix, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.29 |
52 Week High | US$11.31 |
52 Week Low | US$2.00 |
Beta | 1.46 |
1 Month Change | -19.36% |
3 Month Change | -8.31% |
1 Year Change | -1.41% |
3 Year Change | -54.85% |
5 Year Change | 137.36% |
Change since IPO | -52.17% |
Recent News & Updates
Recent updates
Ocular Therapeutics' Impressive Surge: A Strategic Insight
Mar 19Ocular Therapeutix: Diabetic Retinopathy Data Q2 2024 And Wet AMD Advancement
Feb 11Ocular Therapeutix Vies With Gene Therapies, Not Just Eylea, For Wet AMD
Jan 10Optimistic Investors Push Ocular Therapeutix, Inc. (NASDAQ:OCUL) Shares Up 31% But Growth Is Lacking
Jan 09Is Ocular Therapeutix (NASDAQ:OCUL) Using Too Much Debt?
Oct 15Is Ocular Therapeutix (NASDAQ:OCUL) Weighed On By Its Debt Load?
Jun 30Analysts Just Slashed Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) EPS Numbers
Mar 08Is Ocular Therapeutix (NASDAQ:OCUL) Using Debt In A Risky Way?
Feb 11Ocular Therapeutix, Inc. (NASDAQ:OCUL) Analysts Are More Bearish Than They Used To Be
Nov 16Despite Lacking Profits Ocular Therapeutix (NASDAQ:OCUL) Seems To Be On Top Of Its Debt
Sep 09Ocular Therapeutix: Trading Ahead Of An Underappreciated Catalyst Event
Aug 15Some Analysts Just Cut Their Ocular Therapeutix, Inc. (NASDAQ:OCUL) Estimates
May 13Shareholder Returns
OCUL | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | 9.4% | -0.1% | 1.0% |
1Y | -1.4% | 13.6% | 27.2% |
Return vs Industry: OCUL underperformed the US Pharmaceuticals industry which returned 13.6% over the past year.
Return vs Market: OCUL underperformed the US Market which returned 27.2% over the past year.
Price Volatility
OCUL volatility | |
---|---|
OCUL Average Weekly Movement | 14.9% |
Pharmaceuticals Industry Average Movement | 10.4% |
Market Average Movement | 6.0% |
10% most volatile stocks in US Market | 16.2% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: OCUL's share price has been volatile over the past 3 months.
Volatility Over Time: OCUL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2006 | 267 | Pravin Dugel | www.ocutx.com |
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
Ocular Therapeutix, Inc. Fundamentals Summary
OCUL fundamental statistics | |
---|---|
Market cap | US$937.08m |
Earnings (TTM) | -US$115.27m |
Revenue (TTM) | US$59.84m |
16.3x
P/S Ratio-8.5x
P/E RatioIs OCUL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
OCUL income statement (TTM) | |
---|---|
Revenue | US$59.84m |
Cost of Revenue | US$72.44m |
Gross Profit | -US$12.59m |
Other Expenses | US$102.67m |
Earnings | -US$115.27m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.74 |
Gross Margin | -21.04% |
Net Profit Margin | -192.61% |
Debt/Equity Ratio | 16.3% |
How did OCUL perform over the long term?
See historical performance and comparison